HIV and chronic obstructive pulmonary disease: Is it worse and why?

Proceedings of the American Thoracic Society

Volumn 8, Issue 3, 2011, Pages 320-325

  Morris, Alison ^a   George, M Patricia ^a   Crothers, Kristina ^b   Huang, Laurence ^c   Lucht, Lorrie ^a   Kessinger, Cathy ^a   Kleerup, Eric C ^d  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic obstructive pulmonary disease; Emphysema; HIV; Immune reconstitution

Indexed keywords

ANTIRETROVIRUS AGENT;

APOPTOSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION SENSITIVITY; INFLAMMATION; PREVALENCE; RISK FACTOR; SMOKING;

AIRWAY OBSTRUCTION; ANIMALS; ANTI-RETROVIRAL AGENTS; APOPTOSIS; AUTOIMMUNITY; ENDOTHELIAL CELLS; EPITHELIAL CELLS; HEALTH BEHAVIOR; HIV INFECTIONS; HUMANS; INFLAMMATION; LUNG; MACROPHAGES; OXIDATIVE STRESS; PNEUMONIA, PNEUMOCYSTIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; RISK FACTORS; SMOKING; SUBSTANCE-RELATED DISORDERS;

EID: 80051751604     PISSN: 15463222     EISSN: 19435665     Source Type: Journal    
DOI: 10.1513/pats.201006-045WR     Document Type: Conference Paper

References (63)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860. (Pubitemid 28135961)
2. (UNAIDS) Joint UN programme on HIV/AIDS. Global facts and figures. 2009.
3. Louie JK, Hsu LC, Osmond DH, Katz MH, Schwarcz SK. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998. J Infect Dis 2002;186:1023-1027.
4. Grubb JR, Moorman AC, Baker RK, Masur H. The changing spectrum of pulmonary disease in patients with HIV infection on antiretroviral therapy. AIDS 2006;20:1095-1107. (Pubitemid 43786097)
5. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Bethesda, National Heart, Lung, and Blood Institute, December 2009. Available from: wwwgoldCOPDcom.
6. Rosen MJ, Lou Y, Kvale PA, Rao AV, Jordan MC, Miller A, Glassroth J, Reichman LB, Wallace JM, Hopewell PC. Pulmonary Complications of HIV Infection Study Group. Pulmonary function tests in HIV-infected patients without AIDS. Am J Respir Crit Care Med 1995;152:738-745.
7. Mitchell DM, Fleming J, Pinching AJ, Harris JR, Moss FM, Veale D, Shaw RJ. Pulmonary function in human immunodeficiency virus infection: a prospective 18-month study of serial lung function in 474 patients. Am Rev Respir Dis 1992;146:745-751.
8. Gelman M, King MA, Neal DE, Pacht ER, Clanton TL, Diaz PT. Focal air trapping in patients with HIV infection: CT evaluation and correlation with pulmonary function test results. Am J Roentgenol 1999;172:1033-1038. (Pubitemid 29505635)
9. Diaz PT, King MA, Pacht ER, Wewers MD, Gadek JE, Nagaraja HN, Drake J, Clanton TL. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. Ann Intern Med 2000;132:369-372. (Pubitemid 30127775)
10. Diaz PT, Clanton TL, Pacht ER. Emphysema-like pulmonary disease associated with human immunodeficiency virus infection. Ann Intern Med 1992;116:124-128.
11. Crothers K, Butt AA, Gibert CL, Rodriguez-Barradas MC, Crystal S, Justice AC. Increased COPD among HIV-positive compared to HIVnegative veterans. Chest 2006;130:1326-1333. (Pubitemid 44786723)
12. Magalhaes MG, Greenberg B, Hansen H, Glick M. Comorbidities in older patients with HIV: a retrospective study. J Am Dent Assoc 2007;138:1468-1475.
13. George MP, Kannass M, Huang L, Sciurba FC, Morris A. Respiratory symptoms and airway obstruction in HIV-infected subjects in the HAART era. PLoS ONE 2009;4:e6328.
14. Cui Q, Carruthers S, McIvor A, Smaill F, Thabane L, Smieja M. Effect of smoking on lung function, respiratory symptoms and respiratory diseases amongst HIV-positive subjects: a cross-sectional study. AIDS Res Ther 2009;7:6.
15. Gingo M, George MP, Kessinger C, Lucht L, Rissler B, Weinmann R, Slivka W, McMahon D, Wenzel S, Sciurba FC, et al. Pulmonary function abnormalities in HIV-infected patients during the current antiretroviral therapy era. Am J Respir Crit Care Med 2010;182:790-796.
16. Niaura R, Shadel WG, Morrow K, Tashima K, Flanigan T, Abrams DB. Human immunodeficiency virus infection, AIDS, and smoking cessation: The time is now. Clin Infect Dis 2000;31:808-812. (Pubitemid 32295508)
17. Gritz ER, Vidrine DJ, Lazev AB, Amick BC III, Arduino RC. Smoking behavior in a low-income multiethnic HIV/AIDS population. Nicotine Tob Res 2004;6:71-77. (Pubitemid 38372476)
18. Justice AC, Lasky E, McGinnis KA, Skanderson M, Conigliaro J, Fultz SL, Crothers K, Rabeneck L, Rodriguez-Barradas M, Weissman SB, et al. Medical disease and alcohol use among veterans with human immunodeficiency infection: a comparison of disease measurement strategies. Med Care 2006;44:S52-S60. (Pubitemid 44284258)
19. Sethi S. Bacterial infection and the pathogenesis of COPD. Chest 2000;117:286S-291S. (Pubitemid 30326996)
20. Koziel H, Kim S, Reardon C, Li X, Garland R, Pinkston P, Kornfeld H. Enhanced in vivo human immunodeficiency virus-1 replication in the lungs of human immunodeficiency virus-infected persons with Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 1999;160:2048-2055. (Pubitemid 30004717)
21. Shaw RJ, Roussak C, Forster SM, Harris JR, Pinching AJ, Mitchell DM. Lung function abnormalities in patients infected with the human immunodeficiency virus with and without overt pneumonitis. Thorax 1988;43:436-440.
22. Morris AM, Huang L, Bacchetti P, Turner J, Hopewell PC, Wallace JM, Kvale PA, Rosen MJ, Glassroth J, Reichman LB, et al. The Pulmonary Complications of HIV Infection Study Group. Permanent declines in pulmonary function following pneumonia in human immunodeficiency virus-infected persons. Am J Respir Crit Care Med 2000;162:612-616. (Pubitemid 30647208)
23. Morris A, Alexander T, Radhi S, Lucht L, Sciurba FC, Kolls JK, Srivastava R, Steele C, Norris KA. Airway obstruction is increased in Pneumocystis- colonized human immunodeficiency virus-infected outpatients. J Clin Microbiol 2009;47:3773-3776.
24. Christensen PJ, Preston AM, Ling T, Du M, Fields WB, Curtis JL, Beck JM. Pneumocystis murina infection and cigarette smoke exposure interact to cause increased organism burden, development of airspace enlargement, and pulmonary inflammation in mice. Infect Immun 2008;76:3481-3490.
25. Norris KA, Morris A, Patil S, Fernandes E. Pneumocystis colonization, airway inflammation, and pulmonary function decline in acquired immunodeficiency syndrome. Immunol Res 2006;36:175-187. (Pubitemid 46398594)
26. Shipley T, Kling H, Morris A, Patil S, Kristoff J, Guyach S, Murphy J, Shao X, Sciurba F, Rogers R, et al. Persistent Pneumocystis colonization leads to the development of chronic obstructive pulmonary disease (COPD) in a non-human primate model of AIDS. J Infect Dis (In press)
27. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996;153:530-534.
28. Di Stefano A, Capelli A, Lusuardi M, Balbo P, Vecchio C, Maestrelli P, Mapp CE, Fabbri LM, Donner CF, Saetta M. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 1998;158:1277-1285. (Pubitemid 28489033)
29. Pesci A, Balbi B, Majori M, Cacciani G, Bertacco S, Alciato P, Donner CF. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur Respir J 1998;12:380-386. (Pubitemid 28389533)
30. Saetta M, Di Stefano A, Turato G, Facchini FM, Corbino L, Mapp CE, Maestrelli P, Ciaccia A, Fabbri LM. Cd8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:822-826.
31. Twigg HL, Soliman DM, Day RB, Knox KS, Anderson RJ, Wilkes DS, Schnizlein-Bick CT. Lymphocytic alveolitis, bronchoalveolar lavage viral load, and outcome in human immunodeficiency virus infection. Am J Respir Crit Care Med 1999;159:1439-1444. (Pubitemid 29227851)
32. Wang Z, Zheng T, Zhu Z, Homer RJ, Riese RJ, Chapman HA Jr, Shapiro SD, Elias JA. Interferon gamma induction of pulmonary emphysema in the adult murine lung. J Exp Med 2000;192:1587-1600.
33. Twigg HL III, Iwamoto GK, Soliman DM. Role of cytokines in alveolar macrophage accessory cell function in HIV-infected individuals. J Immunol 1992;149:1462-1469.
34. Buhl R, Jaffe HA, Holroyd KJ, Borok Z, Roum JH, Mastrangeli A, Wells FB, Kirby M, Saltini C, Crystal RG. Activation of alveolar macrophages in asymptomatic HIV-infected individuals. J Immunol 1993;150:1019-1028. (Pubitemid 23133682)
35. Yearsley MM, Diaz PT, Knoell D, Nuovo GJ. Correlation of HIV-1 detection and histology in AIDS-associated emphysema. Diagn Mol Pathol 2005;14:48-52. (Pubitemid 40283862)
36. Kaner RJ, Santiago F, Crystal RG. Up-regulation of alveolar macrophage matrix metalloproteinases in HIV-1(+) smokers with early emphysema. J Leukoc Biol 2009;86:913-922.
37. MacNee W, Tuder RM. New paradigms in the pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2009;6:527-531.
38. Buhl R, Meyer A, Vogelmeier C. Oxidant-protease interaction in the lung: rospects for antioxidant therapy. Chest 1996;110:267S-272S. (Pubitemid 26425187)
39. Treitinger A, Spada C, Verdi JC, Miranda AF, Oliveira OV, Silveira MV, Moriel P, Abdalla DS. Decreased antioxidant defence in individuals infected by the human immunodeficiency virus. Eur J Clin Invest 2000;30:454-459. (Pubitemid 30251403)
40. Gil L, Martinez G, Gonzalez I, Tarinas A, Alvarez A, Giuliani A, Molina R, Tapanes R, Perez J, Leon OS. Contribution to characterization of oxidative stress in HIV/AIDS patients. Pharmacol Res 2003;47:217-224. (Pubitemid 36259924)
41. Shatrov VA, Ratter F, Gruber A, Droge W, Lehmann V. HIV type 1 glycoprotein 120 amplifies tumor necrosis factor-induced NF-kappa b activation in jurkat cells. AIDS Res Hum Retroviruses 1996;12:1209-1216. (Pubitemid 26306969)
42. Pacht ER, Diaz P, Clanton T, Hart J, Gadek JE. Alveolar fluid glutathione is not reduced in asymptomatic HIV-seropositive subjects. Am J Respir Crit Care Med 1997;155:374-377. (Pubitemid 27053191)
43. Cole SB, Langkamp-Henken B, Bender BS, Findley K, Herrlinger-Garcia KA, Uphold CR. Oxidative stress and antioxidant capacity in smoking and nonsmoking men with HIV/acquired immunodeficiency syndrome. Nutr Clin Pract 2005;20:662-667. (Pubitemid 41790079)
44. Lassiter C, Fan X, Joshi PC, Jacob BA, Sutliff RL, Jones DP, Koval M, Guidot DM. HIV-1 transgene expression in rats causes oxidant stress and alveolar epithelial barrier dysfunction. AIDS Res Ther 2009;6:1.
45. Aukrust P, Muller F, Svardal AM, Ueland T, Berge RK, Froland SS. Disturbed glutathione metabolism and decreased antioxidant levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: potential immunomodulatory effects of antioxidants. J Infect Dis 2003;188:232-238. (Pubitemid 36898155)
46. Hulgan T, Morrow J, D'Aquila RT, Raffanti S, Morgan M, Rebeiro P, Haas DW. Oxidant stress is increased during treatment of human immunodeficiency virus infection. Clin Infect Dis 2003;37:1711-1717. (Pubitemid 37549961)
47. Demedts IK, Demoor T, Bracke KR, Joos GF, Brusselle GG. Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema. Respir Res 2006;7:53.
48. Kasahara Y, Tuder RM, Cool CD, Lynch DA, Flores SC, Voelkel NF. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med 2001;163:737-744. (Pubitemid 32230838)
49. Tuder RM, McGrath S, Neptune E. The pathobiological mechanisms of emphysema models: what do they have in common? Pulm Pharmacol Ther 2003;16:67-78. (Pubitemid 36369397)
50. Micoli KJ, Mamaeva O, Piller SC, Barker JL, Pan G, Hunter E, McDonald JM. Point mutations in the c-terminus of HIV-1 gp160 reduce apoptosis and calmodulin binding without affecting viral replication. Virology 2006;344:468-479. (Pubitemid 43049633)
51. Micoli KJ, Pan G, Wu Y, Williams JP, Cook WJ, McDonald JM. Requirement of calmodulin binding by HIV-1 gp160 for enhanced fas-mediated apoptosis. J Biol Chem 2000;275:1233-1240. (Pubitemid 30051176)
52. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiebaut R, Morfeldt L, De Wit S, Pradier C, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003.
53. Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG, Cooper DA, Emery S. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007;21:2445-2453. (Pubitemid 350145176)
54. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006;20:2165-2174. (Pubitemid 44684707)
55. Koppel K, Bratt G, Schulman S, Bylund H, Sandstrom E. Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitorcontaining highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002;29:441-449. (Pubitemid 34456334)
56. Diaz PT, King MA, Pacht ER, Wewers MD, Gadek JE, Neal D, Nagaraja HN, Drake J, Clanton TL. The pathophysiology of pulmonary diffusion impairment in human immunodeficiency virus infection. Am J Respir Crit Care Med 1999;160:272-277. (Pubitemid 29326099)
57. Agusti A, MacNee W, Donaldson K, Cosio M. Hypothesis: does COPD have an autoimmune component? Thorax 2003;58:832-834. (Pubitemid 37239227)
58. Lee SH, Goswami S, Grudo A, Song LZ, Bandi V, Goodnight-White S, Green L, Hacken-Bitar J, Huh J, Bakaeen F, et al. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 2007;13:567-569. (Pubitemid 46828488)
59. Zandman-Goddard G, Shoenfeld Y. HIV and autoimmunity. Autoimmun Rev 2002;1:329-337. (Pubitemid 38340245)
60. Calabrese LH, Kirchner E, Shrestha R. Rheumatic complications of human immunodeficiency virus infection in the era of highly active antiretroviral therapy: emergence of a new syndrome of immune reconstitution and changing patterns of disease. Semin Arthitis Rheum 2005;35:166-174. (Pubitemid 41713956)
61. Chen F, Day SL, Metcalfe RA, Sethi G, Kapembwa MS, Brook MG, Churchill D, de Ruiter A, Robinson S, Lacey CJ, et al. Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease. Medicine 2005;84:98-106. (Pubitemid 40418638)
62. Jubault V, Penfornis A, Schillo F, Hoen B, Izembart M, Timsit J, Kazatchkine MD, Gilquin J, Viard JP. Sequential occurrence of thyroid autoantibodies and Graves' disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients. J Clin Endocrinol Metab 2000;85:4254-4257. (Pubitemid 32055382)
63. Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF, Polis MA, Haase AT, Feinberg MB, Sullivan JL, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998;396:690-695. (Pubitemid 29003949)